AbbVie Secures European Marketing Clearance for Giant Cell Arteritis Treatment Rinvoq

, MT Newswires -  3:23 AM ET 4/8/2025 Company News

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

03:23 AM EDT, 04/08/2025 (MT Newswires) -- AbbVie ( ABBV ) said Tuesday that the European Commission granted marketing authorization to giant cell arteritis treatment Rinvoq for adult patients.

The approval was based on results from a phase 3 trial, which met its primary and key secondary endpoints, the company said.

The drug has been previously approved in seven other indications, including rheumatoid arthritis.

Giant cell arteritis is an inflammatory autoimmune disease of large blood vessels.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.